What is the first-line management for insomnia?

First-Line Management of Insomnia

Cognitive Behavioral Therapy for Insomnia (CBT-I) must be initiated as the first-line treatment for all adults with chronic insomnia before any pharmacologic intervention is considered. 1, 2, 3, 4

Why CBT-I is Mandatory First-Line

• CBT-I provides superior long-term efficacy compared to all pharmacologic agents, with therapeutic benefits persisting for up to 2 years after treatment ends, whereas medication effects cease immediately when the drug is stopped. 1, 2, 3
• CBT-I carries minimal risk of adverse effects, no potential for dependence or tolerance, and addresses the underlying perpetuating mechanisms of insomnia rather than merely suppressing symptoms. 1, 5, 6
• The VA/DoD, American Academy of Sleep Medicine, and American College of Physicians all issue strong recommendations for CBT-I as initial therapy, explicitly stating that pharmacotherapy should never be used as monotherapy. 1, 2, 4

Core Components of Effective CBT-I (All Required)

Sleep Restriction Therapy 1, 2, 4

• Limit time in bed to actual sleep time plus 30 minutes (minimum 5 hours allowed) 2, 4
• Adjust weekly based on sleep efficiency (total sleep time ÷ time in bed × 100%) 2, 4
• This creates mild sleep deprivation that strengthens homeostatic sleep drive and consolidates fragmented sleep 2, 4

Stimulus Control Therapy 1, 2, 4

• Use bed only for sleep and sex; leave bed after approximately 20 minutes if unable to fall asleep 2, 4
• Engage in relaxing activity until drowsy, then return to bed 4
• Maintain consistent wake time regardless of sleep duration 2

Cognitive Restructuring 1, 2, 3

• Target maladaptive beliefs such as "I must get 8 hours of sleep" or "My life will be ruined if I don't sleep well tonight" 2, 4
• Use structured psychoeducation, Socratic questioning, and behavioral experiments 2

Relaxation Techniques 1, 2

• Progressive muscle relaxation, guided imagery, controlled breathing exercises 2, 4
• These lower physiological arousal that perpetuates insomnia 4

Sleep Hygiene Education 1, 2, 3

• Avoid caffeine ≥6 hours before bedtime, eliminate evening alcohol, avoid screens ≥1 hour before sleep 2, 4
• Maintain quiet, dark, cool bedroom environment and consistent sleep-wake schedule 2
• Critical caveat: Sleep hygiene education alone is insufficient as monotherapy and must be combined with the other CBT-I components. 1, 2, 3, 4

Delivery Formats (All Equally Effective)

• CBT-I can be delivered via individual therapy, group sessions, telephone-based programs, web-based modules, or self-help books; all formats demonstrate comparable efficacy. 1, 2, 3
• Brief Behavioral Therapy for Insomnia (BBT-I), consisting of 2-4 sessions focusing on behavioral components only, is appropriate when resources are limited. 1, 2
• This addresses the common barrier of limited access to behavioral sleep specialists 1, 2

When to Add Pharmacotherapy (Second-Line Only)

Pharmacologic agents should be added only after CBT-I has been initiated and only if: 1, 2, 3, 4

• CBT-I is insufficient after 4-8 weeks 2
• CBT-I is unavailable despite attempts to access alternative delivery formats 1, 2
• The patient cannot participate in CBT-I due to cognitive impairment or other barriers 2, 3, 4

Pharmacotherapy must never be used as monotherapy; it is intended only as a temporary adjunct to CBT-I. 1, 2, 4

Medication Selection by Insomnia Phenotype (When Necessary)

For Sleep-Onset Insomnia

• Zolpidem 10 mg (5 mg if ≥65 years): Reduces sleep-onset latency by approximately 25 minutes; take within 30 minutes of bedtime with ≥7 hours before awakening 2, 7
• Zaleplon 10 mg (5 mg if ≥65 years): Ultra-short half-life (~1 hour) suitable for middle-of-night dosing when ≥4 hours remain 2
• Ramelteon 8 mg: Melatonin-receptor agonist with no abuse potential; preferred for patients with substance-use history 2, 3

For Sleep-Maintenance Insomnia

• Low-dose doxepin 3-6 mg: Reduces wake after sleep onset by 22-23 minutes via H₁-antagonism; minimal anticholinergic effects and no abuse potential; preferred first-line for maintenance 2, 4
• Suvorexant 10 mg: Orexin-receptor antagonist reducing wake after sleep onset by 16-28 minutes; lower cognitive/psychomotor risk versus benzodiazepine-type agents 2, 4

For Combined Sleep-Onset and Maintenance Insomnia

• Eszopiclone 2-3 mg (1 mg if ≥65 years or hepatic impairment): Increases total sleep time by 28-57 minutes 2, 4
• Zolpidem extended-release: Addresses both onset and maintenance 2

Medications Explicitly NOT Recommended

Trazodone 2, 4

• Only ~10 minute reduction in sleep latency with no improvement in subjective sleep quality 2, 4
• Causes adverse events in ~75% of older adults 2, 4

Over-the-Counter Antihistamines (diphenhydramine, doxylamine) 2, 3, 4

• No efficacy data, strong anticholinergic effects (confusion, urinary retention, falls, delirium) 2, 4
• Tolerance develops within 3-4 days 2, 4

Traditional Benzodiazepines (lorazepam, clonazepam, diazepam) 2, 3

• Long half-lives cause accumulation, daytime sedation, higher fall and cognitive-impairment risk 2
• Linked to dementia and fractures in older adults 2

Antipsychotics (quetiapine, olanzapine) 2, 3, 4

• Weak benefit with significant metabolic and extrapyramidal risks 2, 4
• Increased mortality in elderly patients with dementia 2, 4

Melatonin supplements 2, 3

• Only ~9 minute latency reduction; insufficient evidence for chronic insomnia 2

Herbal supplements (valerian, L-tryptophan, chamomile, kava) 2, 3

• Insufficient evidence to support use for primary insomnia 2
• Kava carries hepatotoxicity risk 1

Age-Adjusted Dosing for Older Adults (≥65 Years)

• Mandatory dose reductions: zolpidem ≤5 mg, eszopiclone ≤2 mg, zaleplon ≤5 mg 2
• Low-dose doxepin 3 mg and ramelteon 8 mg are the safest hypnotic choices for older adults due to minimal fall risk and cognitive impairment 2, 3

Critical Safety Warnings

• All benzodiazepine-receptor agonists carry FDA warnings for complex sleep behaviors (sleep-driving, sleep-walking, sleep-eating); discontinue immediately if these occur. 2
• Avoid concurrent alcohol use with any hypnotic; this markedly raises risk of complex behaviors and respiratory depression. 2
• Monitor older adults for falls, fractures, and cognitive decline while on any hypnotic agent. 2
• FDA labeling limits hypnotic use to ≤4 weeks for acute insomnia; evidence for longer use is insufficient. 2, 7

Implementation Algorithm

Step 1: Initiate CBT-I immediately for all chronic insomnia patients, incorporating all five core components (sleep restriction, stimulus control, cognitive restructuring, relaxation, sleep hygiene education) 1, 2, 3, 4

Step 2: Reassess after 4-8 weeks of CBT-I 2

Step 3: Add pharmacotherapy only if CBT-I response is inadequate, selecting agents based on specific insomnia phenotype (see medication tables above) 1, 2

Step 4: Reassess after 1-2 weeks of any medication to evaluate sleep-onset latency, total sleep time, nocturnal awakenings, daytime functioning, and adverse effects 2

Step 5: If the first agent fails, switch within the same class (e.g., zaleplon → zolpidem for onset; doxepin → suvorexant for maintenance) 2

Step 6: Periodically attempt to taper and discontinue pharmacotherapy while continuing CBT-I 1, 2

Common Pitfalls to Avoid

• Starting hypnotic therapy without first implementing CBT-I violates strong guideline recommendations and leads to less durable benefit. 1, 2, 4
• Relying solely on sleep hygiene education without structured CBT-I (stimulus control and sleep restriction) fails to produce durable improvement. 1, 2, 4
• Using adult dosing in older adults increases fall risk; age-adjusted dosing is essential. 2
• Combining multiple sedative agents markedly raises risk of respiratory depression, cognitive impairment, falls, and complex sleep behaviors. 2, 4
• Continuing pharmacotherapy long-term without periodic reassessment and attempts at discontinuation. 2
• Prescribing trazodone, OTC antihistamines, or antipsychotics for insomnia lacks efficacy and carries significant safety concerns. 2, 3, 4